Ultralife Q3 sales up 21.5% to $43.4M; GAAP loss per share of $0.07 on Calgary closure charge

ULTRALIFE CORP

2025-Q3 EPS reported $0.09 revenue$142,678,000

Sales $43.4M (+21.5% YoY, including Electrochem); organic growth 2.5%. Backlog $90.1M vs $84.5M at Q2 2025.
GAAP EPS ($0.07) vs $0.02; operating loss $1.0M includes $1.1M non-recurring costs (Calgary facility closure).
Gross margin 22.2% down from 24.3% on raw material quality issues; adjusted EBITDA $2.0M vs $1.9M.
Battery & Energy Products sales +22.8% (ex-Electrochem +1.9%); government/defense sales +19.0%.
Calgary closure charge $0.5M; expected annual savings ~$0.8M after completion in Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.